Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma

Future Oncol. 2023 Jun;19(17):1161-1163. doi: 10.2217/fon-2023-0318. Epub 2023 Jun 9.

Authors

Rita Khoury¹, Claude Chahine¹, Rebecca Ibrahim¹, Nadine Khalife², Mohammad Saleh³, Khalil Saleh¹

Affiliations

¹ International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
² Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
³ Department of Hematology & Oncology, Lebanese American University Medical Center-Rizk Hopsital, Beirut, 11-3288, Lebanon.

PMID: 37293779
DOI: 10.2217/fon-2023-0318

No abstract available

Keywords: futibatinib; infigratinib; intrahepatic cholangiocarcinoma; pemigatinib.

Publication types

Editorial

MeSH terms

Bile Duct Neoplasms* / drug therapy
Bile Duct Neoplasms* / pathology
Bile Ducts, Intrahepatic / pathology
Cholangiocarcinoma* / drug therapy
Cholangiocarcinoma* / pathology
Humans
Precision Medicine

Substances

futibatinib